- A rapid, multiplex molecular test kit from Sekisui Diagnostics that detects SARS-CoV-2, Influenza A, and Influenza B from a single nasal swab in about 20 minutes
Uses
-
Simultaneous detection:
- Of COVID-19, Flu A, and Flu B in one test, reducing the need for multiple separate tests
-
Differential diagnosis:
- In patients with respiratory symptoms, helping distinguish between COVID‑19 and influenza
-
Symptomatic screening:
- For individuals aged 2+ (collected by an adult) or 14+ (self‑collected) with respiratory illness consistent with COVID‑19
-
Non‑prescription home use:
- Authorized under FDA EUA for self‑collected specimens
- Suitable for CLIA‑waived settings:
- Minimal operator training is required
Features
-
3-in-1 multiplex:
- Detects all three pathogens from one anterior nasal swab
-
Rapid results:
- ~20 minutes to read results
-
Minimal hands-on time:
- Simple, step-by-step process with minimal operator training
-
No maintenance or calibration:
- Ready for testing at any time
-
Machine-read:
- Designed for the Metrix Reader (Gen 2) for automated interpretation
-
Sample type:
- Anterior nasal swab; no special storage required
-
Pack size:
- 25 complete test kits, each with swabs, collectors, buffer caps, and reaction sensors
- Performance:
- High agreement rates (PPA ~95–99%, NPA ~96–99%) compared to RT-PCR
Benefits
-
Time efficiency:
- Delivers lab-quality results quickly, enabling faster decision-making
-
Cost-effective:
- Reduces testing costs by combining multiple tests into one
-
Operator-friendly:
- Minimal training needed; results are color-coded for easy interpretation
-
Flexible deployment:
- Suitable for various facility types and settings
-
Support:
- Includes online training and experienced support teams for implementation
-
Accessibility:
- No need for lab calibration, making it deployable in diverse environments
